RxDoctor Payments Data

Felicia Gonzalez

Family · Port Allen, LANPI 1831775246

Payments from drug & device makers

$876in general payments, 2019–2025

Across 36 payments — averaging $24.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$259
  • Axsome Therapeutics, Inc.$150
  • Bayer$105
  • Otsuka America Pharmaceutical, Inc.$84
  • Vanda Pharmaceuticals Inc.$77
  • Lilly USA, LLC$36
  • plus $165 from 7 others

What the payments were for

  • Food & beverage$876100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$876 in reported general payments places this provider in the 60th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$3,565
Medicare patients
26
Services billed
86

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin41$40,449
OzempicSemaglutide25$23,347
TrulicityDulaglutide16$17,391
TradjentaLinagliptin12$11,073
Combivent RespimatIpratropium/Albuterol Sulfate19$9,545
Fluticasone Propionate60$1,160
Atorvastatin Calcium109$850
Metformin Hcl90$745
Oseltamivir Phosphate15$475
Albuterol Sulfate HfaAlbuterol Sulfate16$418
Pantoprazole Sodium32$383
Amlodipine Besylate70$296
Rosuvastatin Calcium25$281
Omeprazole14$215
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide11$212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$20$61,06872 claims
Lilly USA, LLCTrulicity$36$17,39116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,610 family providers in Louisiana.

Other family in Port Allen

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →